American International Group Inc. Sells 2,999 Shares of Haemonetics Co. (NYSE:HAE)

American International Group Inc. trimmed its stake in Haemonetics Co. (NYSE:HAE) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 93,060 shares of the medical instruments supplier’s stock after selling 2,999 shares during the quarter. American International Group Inc. owned 0.18% of Haemonetics worth $7,958,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Westfield Capital Management Co. LP boosted its holdings in Haemonetics by 27.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock worth $60,888,000 after acquiring an additional 152,098 shares in the last quarter. Isthmus Partners LLC purchased a new position in shares of Haemonetics in the fourth quarter worth $1,530,000. Vanguard Group Inc. raised its stake in shares of Haemonetics by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after purchasing an additional 27,146 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Haemonetics in the fourth quarter worth $888,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Haemonetics in the fourth quarter worth $2,039,000. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HAE. Barrington Research boosted their price target on Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. JMP Securities boosted their price target on Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a research note on Friday, May 10th. Needham & Company LLC upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target for the company in a research note on Wednesday, June 12th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $109.50.

Haemonetics Stock Down 0.2 %

Haemonetics stock opened at $85.40 on Thursday. The stock has a market cap of $4.35 billion, a PE ratio of 37.29, a price-to-earnings-growth ratio of 1.56 and a beta of 0.37. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.50 and a current ratio of 2.56. Haemonetics Co. has a one year low of $70.74 and a one year high of $97.97. The stock has a fifty day moving average of $88.93 and a 200 day moving average of $83.67.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.02. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The business had revenue of $343.00 million during the quarter, compared to analyst estimates of $329.53 million. During the same quarter in the previous year, the company posted $0.77 earnings per share. Haemonetics’s revenue for the quarter was up 12.7% on a year-over-year basis. As a group, sell-side analysts predict that Haemonetics Co. will post 4.57 EPS for the current year.

Insider Buying and Selling at Haemonetics

In other Haemonetics news, insider Stewart W. Strong sold 733 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $96.04, for a total transaction of $70,397.32. Following the completion of the sale, the insider now owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Stewart W. Strong sold 733 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $96.04, for a total value of $70,397.32. Following the completion of the transaction, the insider now owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Anila Lingamneni sold 2,305 shares of the company’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the completion of the transaction, the executive vice president now directly owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,380 shares of company stock valued at $2,445,816. Company insiders own 1.80% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.